News

Smoking Contributes to Progression of ALS and Decreases Survival, Study Finds

Smoking contributes to disease progression in amyotrophic lateral sclerosis (ALS) and decreases patient survival by about two years regardless of age, gender, or other disease modifiers such as respiratory function, chronic obstructive pulmonary disease (COPD) and ALS-associated gene mutations, according to new research. These findings suggest that neurologists should advise…

Neuroimaging Techniques Confirm Neuropathological Findings that Contribute to Degeneration in ALS

Advanced neuroimaging techniques and neuropsychological evaluations of patients with amyotrophic lateral sclerosis (ALS) recently confirmed the existence of a unique micro-structural brain degeneration pattern that contributes to memory loss, according to a study conducted by an international research team that included a group from Baylor College of Medicine. The report, “…

FDA Approves Test of Combined Stem Cell and Gene Therapy for ALS

Regenerative medicine investigators at the Cedars-Sinai Medical Center have received U.S. Food and Drug Administration (FDA) approval to test a novel combination stem cell-gene therapy they’ve developed to stall amyotrophic lateral sclerosis (ALS) progression. Enrollment in the trial is expected to commence soon. Also known as Lou Gehrig’s disease, ALS is…

Damage to Brain Areas Crucial to Thinking, Not Motor Neurons, Seen as Root of ALS Cognitive Problems

Amyotrophic lateral sclerosis (ALS) patients with cognitive difficulties show brain damage in areas important to thinking, a finding that may explain why such patients deteriorate more rapidly. The study, “Structural explanation of poor prognosis of amyotrophic lateral sclerosis in the non-demented state,” published in the European Journal of Neurology, also supports…

ALS Patients with Emotion Recognition Problems May Improve with Positive Social Contact, Study Finds

Researchers in a recent amyotrophic lateral sclerosis (ALS) study found that patients had problems reading negative emotions in other people because of changed activity in brain regions associated with emotional recognition. Conversely, patients with more frequent social contacts were able to neurologically compensate. The study, “Perception of emotional facial expressions in amyotrophic…

FDA Names Ibudilast an Orphan Drug as Possible ALS Treatment

The U.S. Food and Drug Administration (FDA) has designated  MediciNova’s Ibudilast (MN-166) an orphan drug as a potential treatment for amyotrophic lateral sclerosis (ALS). Ibudilast is a first-in-class, orally bioavailable small molecule phosphodiesterase (PDE)-4 and -10 inhibitor and a macrophage migration inhibitory factor (MIF) inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors.